Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | S100A9 | P06702 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CCR4 | P51679 | 6/20 | 0.37 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2005246 | 0.80 | PLAU (0.40) | CYP2C9LMNATSHRAPEX1SMN1; SMN2 | |
| SCHEMBL26693926 | 0.79 | PLAU (0.39) | CYP2C9LMNATSHRAPEX1SMN1; SMN2 | |
| SCHEMBL29837826 | 0.79 | PLAU (0.39) | CYP2C9LMNATSHRAPEX1SMN1; SMN2 | |
| SCHEMBL7055864 | 0.78 | SMN1; SMN2 (0.64) | CYP2C9LMNATSHRAPEX1SMN1; SMN2 | |
| SCHEMBL2655524 | 0.78 | MAPT (0.39) | S100A9MAPTCASP1 | |
| SCHEMBL1882789 | 0.78 | HTT (0.46) | CYP2C9SMN1; SMN2S100A9MAPTCASP1 | |
| SCHEMBL17450942 | 0.78 | MAPT (0.45) | SMN1; SMN2CCR4MAPTCASP1 | |
| SCHEMBL29102860 | 0.77 | S100A9 (0.37) | S100A9MAPTCASP1 | |
| SCHEMBL1845695 | 0.77 | SLC13A5 (0.37) | CYP2C9LMNASMN1; SMN2S100A9MAPK1 | |
| SCHEMBL6954046 | 0.77 | SMN1; SMN2 (0.47) | CYP2C9LMNATSHRAPEX1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4638438-A1 | ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF | Xinthera, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4629985-A1 | TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | Poseidon Innovation 1, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-4629986-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | Poseidon Innovation 1, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-4629987-A1 | TREATMENT OF MYELOPROLIFERATIVE DISEASES AND DISORDERS WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | Poseidon Innovation 1, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250179059-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| WO-2025078654-A1 | ANTIBACTERIAL COMPOUNDS | VEIRULENCE LTD (GB) | 2025-04-17 | — | — | WO | disclosed |
| CN-119661503-A | 4-Ethynyl pyridine derivatives as GCN2 inhibitors | IP2IPO创新有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-116113629-B | 4-Ethynyl pyridine derivatives as GCN2 inhibitors | IP2IPO创新有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20060173006-A1 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-03 | — | — | US | disclosed |
| EP-1660428-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019151-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| US-5681840-A | ANTIDOPAMINERGIC AGENTS | ZENECA LIMITED (GB) | 1997-10-28 | — | — | US | disclosed |
| EP-0533344-B1 | Methanoanthracenes as dopamine antagonists | ZENECA LTD (GB) | 1996-10-16 | — | — | EP | disclosed |
| US-5512575-A | ANTISEROTONINE AGENT | ZENECA LIMITED (GB) | 1996-04-30 | — | — | US | disclosed |
| EP-0533344-A1 | Methanoanthracenes as dopamine antagonists | ZENECA LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
| EP-0178633-B1 | 2-phenylpyrano[2,3-b]pyridines | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-01-08 | — | — | EP | disclosed |
| US-4588733-A | 2-phenylpyrano[2,3-b]pyridines and their use in inhibiting viruses | MERRELL DOW PHARMACEUTICALS INC. (US) | 1986-05-13 | — | — | US | disclosed |
| EP-0178633-A2 | 2-phenylpyrano[2,3-b]pyridines | MERRELL DOW PHARMACEUTICALS INC. (US) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179059-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | CYP2C9 4141/4885LMNA 4337/4885TSHR 4508/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | CYP2C9 3575/4885LMNA 1204/4885TSHR 437/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | CYP2C9 2095/4885LMNA 2986/4885TSHR 204/4885 |
| US-20060173006-A1 | Compounds for inflammation and immune-related uses | CXCL8, CCR8, CXCR2 | CYP2C9 189/4885LMNA 3080/4885TSHR 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.